Pharmacotherapy of mood disorders in epilepsy: The role of newer psychotropic drugs

Current Treatment Options in Neurology

Volumn 7, Issue 4, 2005, Pages 281-290

  Kanner, Andres M ^a   Balabanov, Antoaneta J ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMOXAPINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; GABAPENTIN; LAMOTRIGINE; MAPROTILINE; MIRTAZAPINE; NEW DRUG; NORADRENALIN UPTAKE INHIBITOR; OXCARBAZEPINE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; UNINDEXED DRUG; VENLAFAXINE;

ANXIETY DISORDER; BIPOLAR DISORDER; CLINICAL FEATURE; COMORBIDITY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG CHOICE; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERANCE; DYSTHYMIA; ELECTROCONVULSIVE THERAPY; EPILEPSY; FOCAL EPILEPSY; FRONTAL LOBE EPILEPSY; GENERALIZED ANXIETY DISORDER; HUMAN; MOOD DISORDER; PANIC; PREVALENCE; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; REMISSION; REVIEW; SEIZURE; SYMPTOM; TEMPORAL LOBE EPILEPSY;

EID: 22544448664     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-005-0038-7     Document Type: Review

References (58)

1. Jacoby A, Baker GA, Steen N, et al.: The clinical course of epilepsy and its psychosocial correlates: Findings from a UK community study. Epilepsia 1996, 37:148-161.
2. Anthony JC, Eaton WW, Henderson AS: Psychiatric epidemiology. Epidemiol Rev 1995, 17:240-242.
3. Kogeorgos J, Fonagy P, Scott D, et al.: Psychiatric symptom patterns of chronic epileptics attending a neurologic clinic: a controlled investigation. Br J Psychiatry 1982, 140:236-244.
4. Mendez MF, Cummings J, Benson D, et al.: Depression in epilepsy: significance and phenomenology. Arch Neurol 1986, 43:766-770.
5. Regier DA, Farmer ME, Rae DS, et al.: One-month prevalence of mental disorders in the United States and socio-demographic characteristics: the Epidemiologic Catchment Area Study. Acta Psychiatr Scan 1993, 88:35-47
6. Kessler RC, McGonagle KA, Zhao S, et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the national comorbidity study. Arch Gen Psychiatr 1994, 51:8-19.
7. Anthony JC, Eaton WW, Henderson AS: Looking to the future in psychiatric epidemiology. Epidemiol Rev 1995, 17:240-242.
8. Blumer D, Zielinski J: Pharmacologic treatment of psychiatric disorders associated with epilepsy. J Epilepsy 1988, 1:135-150.
9. Barraclough B: The suicide rate of epilepsy. Acta Psych Scand 1987, 76:339-345.
10. Gilliam F: Optimizing health outcomes in active epilepsy. Neurology 2002, 58(Suppl 5):S9-S19.
11. Cramer JA, Blum D, Fanning K, Reed M: Epilepsy Impact Project Group. The impact of comorbid depression on health resource utilization in a community sample of people with epilepsy. Epilepsy Behav 2004, 5:337-342.
12. Rafnsson V, Olafsson E, Hauser WA, et al.: Cause-specific mortality in adults with unprovoked seizures. A population-based incidence cohort study. Neuroepidemiology 2001, 20:232-236.
13. Nilsson L, Tomson T, Farahmand BY, et al.: Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. Epilepsia 1997, 38:1062-1068.
14. Hauser WA, Annegers JF, Elveback IR: Mortality in patients with epilepsy. Epilepsia 1980, 21:399-412.
15. Indaco A, Carrieri PB, Nappi C, et al.: Interictal depression in epilepsy. Epilpesy Res 1992, 12:45-50.
16. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (Text Revision), Fourth Edition. Washington, DC: American Psychiatric Association, 2000.
17. Stahl SM, ed: Depression and bipolar disorders. In Essential Pharmacology: Neuroscientific Basis and Practical Applications. Second Edition. New York: Cambridge University Press; 2000:135-197.
18. Hirschfield RMA, Bowden CL, Gitlin MJ, et al.: Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 2002, 159(Suppl 4):1-15.
19. Elkin T, Shea MT, Watkins JT, et al.: National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatment. Arch Gen Psychiatry 1989, 46:971-982.
20. Charney DS, Berman RM, Miller HL: Treatment of depression. In Textbook of Psychopharmacology, Second Edition. Edited by Schatzberg AF and Nemeroff CB. Washington, DC: American Psychiatric Association Press; 1998:705-732.
21. Paykel ES, Ramana R, Cooper Z, et al.: Residual symptoms after partial remission; an important outcome in depression. Psychol Med 1995, 25:1171-1180.
22. Blanchet P, Frommer GP: Mood change preceding epileptic seizures. J Nerv Ment Dis 1986, 174:471-476.
23. Kanner AM, Soto A, Gross-Kanner H: Prevalence and clinical characteristics of postictal psychiatric symptoms in partial epilepsy. Neurology 2004, 62:708-713.
24. Hancock J, Bevilacqua A: Temporal lobe dysrhythmia and impulsive and suicide behavior. South Med J 1971 64:1189-1193.
25. Tollefson GD, Rosenbaum JF: Selective serotonin reuptake inhibitors. In Textbook of Psychopharmacology, Second Edition. Edited by Schatzberg AF and Nemeroff CB. Washington, DC: American Psychiatric Association Press; 1998:219-237.
26. Kent JM, Gorman JM: Venlafaxine. In Textbook of Psychopharmacology, Second Edition. Schatzberg AF and Nemeroff CB. Washington, DC: American Psychiatric Association Press; 1998:301-306.
27. Kanner AM, Balabanov A: Depression in epilepsy: How closely related are these two disorders?. Neurology 2002, 58(Suppl 5):S27-39.
28. Rosenstein D, Nelson J, Jacobs S: Seizures associated with antidepressants: a review. J Clin Psych 1993, 54:289-299.
29. Preskorn S, Fast G: Tricyclic antidepressant induced seizures and plasma drug concentration. J Clin Psych 1992, 53:160-162.
30. Curran S, DePauw: Selecting an antidepressant for use in a patient with epilepsy. Safety considerations. Drug Safety 1998, 18:125-133.
31. Swinkels J, Jonghe F: Safety of antidepressants. Int Clin Psychopharmacol 1995, 9(Supp 4):19-25.
32. Kanner AM, Kozak AM, Frey M: The use of sertraline in patients with epilepsy: is it safe? Epilepsy Behav 2000, 1:100-105.
33. Grimsley S, Jann M, Carter J, et al.: Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991, 50:10-15.
34. Pearson H: Interaction of fluoxetine and carbamazepine. J of Clin Psychiatry 1990, 51:126.
35. Fritze J, Unsorg B, Lanczik M: Interaction between carbamazepine and fluvoxamine. Acta Psych Scand 1991, 84:583-584.
36. Post R, Putnam F, Uhde T: Electroconvulsive therapy as an anticonvulsant: implications for its mechanisms of action in affective illness. Electroconvulsive Therapy: Clinical and Basic Research Issues. Edited by Malitz S, Sackeim H. New York: New York Academy of Sciences; 1986.
37. Blackwood DHR, Cull RE, Freeman CP, et al.: A study of the incidence of epilepsy following EGT. J Neurol Neurosurg Psychiatry 1980, 43:1098-1102.
38. Abrams R: Electroconvulsive therapy in the high-risk patient. In: In Electroconvulsive therapy. New York: Oxford University Press; 1997:81-113.
39. Sackeim HA: The anticonvulsant hypothesis of the mechanisms of action of ECT: current status. J ECT 1999, 15:5-26.
40. Viparelli U, Viparelli G: ECT and grand mal epilepsy. Convuls Ther 1992, 8:39-42.
41. Coffey CE, Lucke J, Weiner RD, et al.: Seizure threshold in electroconvulsive therapy (ECT) II. The anticonvulsant effect of ECT. Biol Psychiatry 1995, 37:777-788.
42. Sackeim HA, Decina P, Prohovnik I, et al.: Anticonvulsant and antidepressant properties of electroconvulsive therapy: a proposed mechanism of action. Biol Psychiatry 1983, 18:1301-1310.
43. Regenold WT, Weintraub D, Taller A: Electroconvulsive therapy for epilepsy and major depression. Am J Geriatr Psychiatry 1998, 6:180-183.
44. Fink M, Kellner C, Sackheim HA: Intractable seizures, status epilepticus and ECT. JECT Lett 1999, 15:282-284.
45. Blum D, Reed M, Metz A: Prevalence of major affective disorders and manic/hypomanic symptoms in persons with epilepsy: A community survey. Neurology 2002, (Suppl 3):A-175.
46. Delucchi GA, Calabrese JR: Anticonvulsants for the treatment of manic depression. Cleveland Clin J Med 1989, 56:756-761.
47. Barry JJ, Lembke A, Huynh N: Affective disorders in epilepsy. In Psychiatric Issues in Epilepsy: A Practical Guide to Diagnosis and Treatment. Edited by Ettinger AB and Kanner AM. Philadelphia: Lippincott Williams & Wilkins; 2001:45-72.
48. Lithium neuroleptic interactions: electroencephalographic studies. Res Commun Psychology Psychiatry Behav 1991, 16:35-40.
49. Bell AJ, Cole A, Eccleston D, et al.: Lithium neurotoxicity at normal therapeutic levels. Br J Psychiatry 1993, 162:688-692.
50. Whitworth AB, Fleischhacker WW: Adverse effects of antipsychotic drugs. Int Clin Psychopharmacol 1995, 9(Suppl 5):21-27.
51. Stahl SM, ed: Depression and bipolar disorders. In Essential Pharmacology: Neuroscientific Basis and Practical Applications. Second Edition. New York: Cambridge University Press; 2000:135-197.
52. Logothetis J: Spontaneous epileptic seizures and EEG changes in the course of phenothiazine therapy. Neurology 1967, 17:869-877.
53. Toth P, Frankenburg FR: Clozapine and seizures: a review. Can J Psychiatry 1994, 39:236-238.
54. Pacia DV, Devinsky O: Clozapine related seizures. Neurology 1994, 44:2247-2249.
55. Tiihonen J, Nousiainen U, Hakola P, et al.: EEG abnormalities associated with clozapine treatment [letter]. Am J Psychiatry 1991, 148:1406.
56. Fatemi SH, Rapport DJ, Calabrese JR, Thuras P: Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 1997, 58:522-527.
57. Fogelson DL, Sternbach H: Lamotrigine treatment of refractory bipolar disorder. J Clin Psych 1997, 58:271-273.
58. Sporn J, Sachs G: The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997, 17:185-189.